Cardiff Oncology, INC 8-K filings

Cardiff Oncology announced positive Phase 2 data for onvansertib in first-line RAS-mutated mCRC, aligned with the FDA on a registrational trial set for Q1 2027, and secured $10 million in financing, but still requires additional funding.

Cardiff Oncology announced a $10 million registered direct offering of common stock and warrants to fund working capital and general corporate purposes.

Cardiff Oncology announced positive Phase 2 data for onvansertib in combination with chemotherapy and bevacizumab for first-line RAS-mutated metastatic colorectal cancer, paving the way for a pivotal Phase 3 trial.

Cardiff Oncology is contesting a purported termination of its 2017 license agreement with Nerviano Medical Sciences.

Cardiff Oncology has filed a lawsuit against Nerviano Medical Sciences (NMS) to dispute allegations of a material breach of their license agreement for onvansertib.

Cardiff Oncology announced first quarter 2026 financial results, highlighting a successful End-of-Phase 2 meeting with the FDA for its onvansertib Phase 3 trial and updated clinical data presentations.

Cardiff Oncology announced key leadership appointments, including a new CEO, CFO, and COO, to drive the company's growth and advance its pipeline.

Cardiff Oncology has formalized separation agreements with its former CEO and CFO, detailing severance payments and consulting arrangements.

Cardiff Oncology reports positive Phase 2 data for Onvansertib in first-line RAS-mutant mCRC, showing significant improvement in objective response rates and progression-free survival, leading to plans for a registrational trial.

Cardiff Oncology announced positive full-year 2025 financial results and compelling Phase 2 CRDF-004 trial data for onvansertib in RAS-mutated mCRC, supporting advancement to registrational development.

Cardiff Oncology announced a leadership transition with a new interim CEO and positive Phase 2 clinical trial results for onvansertib in RAS-mutated metastatic colorectal cancer.

Cardiff Oncology announced encouraging Phase 2 trial results for onvansertib in RAS-mutated metastatic colorectal cancer and extended its cash runway into Q1 2027.

Cardiff Oncology announced positive Phase 2 clinical trial results for onvansertib in first-line RAS-mutated metastatic colorectal cancer, showing a significant improvement in objective response rates and a dose-dependent effect, alongside a cash runway extended into Q1 2027.

Cardiff Oncology, Inc. announced the successful re-election of all seven director nominees, ratification of its independent auditor, approval of an amendment to increase shares under its equity incentive plan, and advisory approval of executive compensation at its Annual Meeting of Stockholders on June 26, 2025.

Cardiff Oncology, Inc. has announced the appointment of Dr. Roger Sidhu, a seasoned oncology executive, as its new Chief Medical Officer, succeeding Dr. Fairooz Kabbinavar, and simultaneously set a date for an important clinical data update from its CRDF-004 trial.

Cardiff Oncology reports completion of enrollment in a Phase 2 trial for RAS-mutated metastatic colorectal cancer and provides a business update, including financial results for Q1 2025.

Cardiff Oncology announced positive clinical data from its lead program in first-line RAS-mut mCRC, a successful $40 million financing, and a cash runway projected into Q1 2027.

Cardiff Oncology's Board of Directors has approved amended and restated by-laws, updating the company's governance procedures.

Cardiff Oncology has priced an underwritten offering of 15,384,619 shares of its common stock at $2.60 per share, expected to raise approximately $40 million in gross proceeds.

Cardiff Oncology's Phase 2 trial of onvansertib in combination with standard-of-care for first-line RAS-mutated metastatic colorectal cancer shows a 64% objective response rate in the 30mg dose arm.

Cardiff Oncology reported positive Phase 2 trial results for onvansertib in second-line KRAS mutant mCRC and anticipates initial data from a first-line trial by the end of 2024.

Cardiff Oncology reported its second quarter 2024 financial results, highlighted by a $60 million cash balance and an anticipated data readout for its CRDF-004 trial in the second half of 2024.

Cardiff Oncology successfully held its annual meeting, electing all director nominees and approving key proposals including the ratification of the company's accounting firm and an increase in shares issuable under the equity incentive plan.

Cardiff Oncology has amended its bylaws to clarify voting standards and rescinded and re-granted stock options to employees and officers, pending shareholder approval.

Cardiff Oncology announced promising clinical trial results and a solid financial position, with a cash runway projected into Q3 2025.

Cardiff Oncology announced the presentation of five abstracts at the AACR annual meeting, highlighting the potential of onvansertib in treating various cancers, particularly RAS-mutated metastatic colorectal cancer.

Cardiff Oncology reports positive clinical data from its second-line ONSEMBLE trial and announces the first patient dosed in its first-line Phase 2 trial for RAS-mutated metastatic colorectal cancer, alongside its 2023 financial results.